LONDON (Reuters) - AstraZeneca said a closely watched experimental cancer drug failed in a clinical trial when used on its own to treat mesothelioma, a rare lung and abdominal cancer, but it remained confident the drug had a role to play in combination treatments.
Tremelimumab failed to meet the primary endpoint of improving overall survival in hard-to-treat mesothelioma patients, the drugmaker said on Monday.
Tremelimumab is an investigational, selective human antibody directed against cytotoxic T- lymphocyte-associated protein 4 (CTLA-4).
Tremelimumab is also being tested in combination with AstraZeneca's anti-PD-L1 investigational immunotherapy durvalumab in multiple tumour types, including non-small cell lung cancer.
"We are disappointed that tremelimumab monotherapy did not demonstrate a survival benefit in this patient population with no approved medicines beyond first-line treatment, Robert Iannone, Senior Vice President, Head of Immuno-Oncology, Global Medicines Development at AstraZeneca, said in a statement. "However, we remain confident in tremelimumab's clinical activity in combination, as shown in our recently published Study 006 trial of tremelimumab and durvalumab in non-small cell lung cancer."